© 2006 European Society of Cardiology
NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial
The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, University of Otago, and the Department of Cardiology Christchurch Hospital, Christchurch, New Zealand
* Corresponding author. Tel.: +64 3 364 1116; fax: +64 3 364 1115. E-mail address: barbara.griffin{at}chmeds.ac.nz
| Abstract |
|---|
Background: How best to decide when to introduce drugs and what doses are optimal in individual patients with chronic heart failure (CHF), is unclear.
Aims: We will determine whether titration of drug treatment according to plasma NTproBNP is superior regarding clinical outcomes to intensive standardised clinical assessment; whether either of the regimens noted above is superior to usual care; and whether age alters the relative efficacy of NTproBNP guided treatment.
Methods: We will randomise 360 patients, stratified by age, to drug treatment directed by plasma NTproBNP, to intensive standardised clinical assessment, or to usual care. The primary outcome is total mortality, and secondary outcomes include death plus hospital admission for any cardiovascular event plus episodes of outpatient decompensated heart failure. Analyses will be conducted at the end of one and two years.
Results: 308 patients have been recruited, the majority being in NYHA functional class II, 60.6% being >75 years. The entry plasma NTproBNP level is 238, 50–1250 pmol/l, median and range, approximately 400–11,000 pg/ml.
Conclusion: sWe describe details of a study to test the potential utility of serial measurements of NTproBNP in adjusting the drug treatment of patients with CHF. Projected completion date is 2007.
Key Words: Chronic heart failure BNP NTproBNP Drug therapy
Received December 12, 2005; Revised March 8, 2006; Accepted April 13, 2006
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. K. Saenger, D. A. Dalenberg, S. C. Bryant, S. K. Grebe, and A. S. Jaffe Pediatric Brain Natriuretic Peptide Concentrations Vary with Age and Sex and Appear to Be Modulated by Testosterone Clin. Chem., October 1, 2009; 55(10): 1869 - 1875. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G.F. Cleland, A. P. Coletta, A. Torabi, and A. L. Clark Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF Eur J Heart Fail, August 1, 2009; 11(8): 802 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Frankenstein, A. Remppis, J. Frankenstein, G. Hess, D. Zdunek, K. Slottje, H. A. Katus, and C. Zugck Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables Clin. Chem., May 1, 2009; 55(5): 923 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vassalle and M. G. Andreassi Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon? Clin. Chem., May 1, 2009; 55(5): 878 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department QJM, November 1, 2008; 101(11): 831 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement Clin. Chem., November 1, 2008; 54(11): 1780 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al. State of the art: Using natriuretic peptide levels in clinical practice Eur J Heart Fail, September 1, 2008; 10(9): 824 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Waldo, J. Beede, S. Isakson, S. Villard-Saussine, J. Fareh, P. Clopton, R. L. Fitzgerald, and A. S. Maisel Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1874 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M. Richards Variability of NT-proBNP levels in heart failure: implications for clinical application Heart, August 1, 2007; 93(8): 899 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hogenhuis, A. A. Voors, T. Jaarsma, A. W. Hoes, H. L. Hillege, J. A. Kragten, and D. J. van Veldhuisen Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure Eur J Heart Fail, August 1, 2007; 9(8): 787 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Breidthardt, K. Laule, A.-H. Strohmeyer, C. Schindler, S. Meier, M. Fischer, A. Scholer, M. Noveanu, M. Christ, A. P. Perruchoud, et al. Medical and Economic Long-term Effects of B-Type Natriuretic Peptide Testing in Patients with Acute Dyspnea Clin. Chem., August 1, 2007; 53(8): 1415 - 1422. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF] |
||||
![]() |
M. A. Konstam Natriuretic Peptides and Cardiovascular Events: More Than a Stretch JAMA, January 10, 2007; 297(2): 212 - 214. [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2575 - 2583. [Full Text] [PDF] |
||||






